Starpharma closer to VivaGel approval in Europe and US
23 November, 2011 by Dylan Bushell-EmblingThe terms of Starpharma's (ASX:SPL) phase III trial for its VivaGel bacterial vaginosis treatment have now been endorsed by both the European EMA and the US FDA.
HealthLinx partners to distribute OvPlex in Spain
23 November, 2011 by Dylan Bushell-EmblingBiomarker specialist HealthLinx (ASX:HTX) has signed an exclusive agreement with a Spanish partner for its OvPlex ovarian cancer diagnostics product.
Phospagenics gets ethics nod for lead product trial
22 November, 2011 by Dylan Bushell-EmblingVictoria's Phosphagenics (ASX:POH) will commence clinical trials of its lead oxycodone delivery patch product at the end of the month, after securing ethics approval.
Hear, hear: Graeme Clark wins Florey Medal
21 November, 2011 by Tim DeanProfessor Graeme Clark, inventor of the bionic ear, has won the CSL Florey Medal, and plans to return to research to further improve the device.
Vale Michael Hirshorn, life science leader
21 November, 2011 by Staff WritersDr Michael Hirshorn, a leader in the life science industry and co-founder of Cochlear and Resmed, lost his battle with cancer on Friday 18 November 2011.
CogState signs $2.6m contract for clinical trials technology
17 November, 2011 by Staff WritersCogState (ASX:CGS) has signed a $2.6m contract with an international pharmaceutical company to use its cognition tests in a clinical trial of depression.
Members invited to AusBiotech state Christmas events
17 November, 2011 by AusBiotechWith Christmas just around the corner, AusBiotech's CEO will be hosting state-based events around the country to celebrate the festive season and the year.
Mesoblast stem cell trial shows reduced heart failure risk
17 November, 2011 by Dylan Bushell-EmblingMesoblast's stem cell treatment for cardiovascular conditions is the first to have shown efficacy in treating the main causes of congestive heart failure.
Starpharma raises $32m to fund VivaGel trial
16 November, 2011 by Dylan Bushell-EmblingStarpharma Holdings (ASX:SPL) has raised $32 million in a placement, and will seek a further $3 million in a SPP, to help fund clinical trials and new product development.
Comment invited on R&D Tax Incentive Discussion Paper
15 November, 2011 by AusBiotechAusIndustry has released a Discussion Paper on the R&D Tax Incentive in an effort to engage with a wide range of audiences to encourage an innovation culture and enable the development of strong guidance material for the new R&D Tax Incentive.
Psivida plummets after FDA knockback
15 November, 2011 by Tim DeanShare price drops by over 50% as FDA demands two more clinical trials for Psivida's flagship treatment, Iluvien, before it's approved for sale.
Phosphagenics raises $3 million in oversubscribed SPP
14 November, 2011 by Dylan Bushell-EmblingVictoria-based Phospagenics (ASX:POH) has raised $3 million in a heavily oversubscribed share purchasing plan to fund the development of its targeted drug delivery products.
Broadvector acquires CSIRO prostate cancer vaccine IP
11 November, 2011 by Dylan Bushell-EmblingBroadvector has completed acquisition of IP from CSIRO for early-stage prostate cancer therapy and prostate cancer vaccine, with CSIRO becoming a major shareholder in the company.
Mesoblast posts successful results from diabetes stem cell trial
10 November, 2011 by Tim DeanA pre-clinical animal trial of Mesoblast's (ASX:MSB) stem cell treatment for Type 2 diabetes has shown positive results, with phase II trial planned for 2012.
Sunshine Heart sees positive results in heart pump trial
10 November, 2011 by Dylan Bushell-EmblingFeasibility trial shows Sunshine Heart's (ASX:SHC) C-Pulse heart pump significantly improved heart function, setting the stage for more thorough testing in 2012.
